Halder Venture allots 7.93 lakh warrants to non-promoter group
Halder Venture Limited allotted 7,93,650 equity convertible warrants to P.K. Bio Link Private Limited at ₹315 per unit. The deal received regulatory clearances from NSE and BSE and shareholder approval via postal ballot in April 2026.

*this image is generated using AI for illustrative purposes only.
Halder Venture Limited has allotted 7,93,650 equity convertible warrants on a preferential basis to the non-promoter group, marking a key step in its capital raising efforts. The allotment was approved by the Board of Directors during a meeting held on July 24, 2026, and follows prior shareholder consent obtained via postal ballot on April 29, 2026. The move allows the company to raise funds while offering subscription rights for future equity participation to the allottee.
The warrants were issued to P.K. Bio Link Private Limited, categorized as a non-promoter entity. Each warrant carries a face value of ₹10 and was allotted at a price of ₹315 per warrant, which includes a premium of ₹305. The instrument entitles the holder to subscribe for an equivalent number of fully paid-up equity shares of Halder Venture Limited in dematerialized form. The company confirmed that it has already received 25% of the subscription amount from the warrant holder as part of the transaction process.
Transaction Details
The preferential allotment was executed in compliance with regulatory requirements and internal governance protocols. The Board approved the specific terms of the issue, including the pricing and the identity of the allottee. The transaction structure ensures that the warrants are issued in demat form, facilitating ease of transfer and eventual conversion into equity shares.
| Allottee Name | Category | Warrants Allotted | Price Per Warrant (₹) |
|---|---|---|---|
| P.K. Bio Link Private Limited | Non-Promoter | 7,93,650 | 315 |
Regulatory Approvals and Compliance
The issuance was conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously secured in-principle approvals from both major stock exchanges. The Bombay Stock Exchange granted approval via Letter no. LOD/PREF/PB/FIP/480/2026-27, while the National Stock Exchange provided approval via Ref: NSE/LIST/54346 dated July 09, 2026.
Shareholder approval for the preferential allotment was obtained through a postal ballot process concluded on April 29, 2026. The Board meeting where the final allotment was approved commenced at 3:00 PM and concluded at 4:15 PM on July 24, 2026. Ayanti Sen, Company Secretary and Compliance Officer of Halder Venture Limited, signed the intimation filed with the exchanges.
What the Numbers Show
The allocation of nearly 8 lakh warrants to a single non-promoter entity indicates a concentrated interest from institutional or high-net-worth investors in Halder Venture’s future equity upside. By setting the warrant price at ₹315 with a ₹305 premium over the ₹10 face value, the company has structured the instrument to reflect significant value beyond nominal capital, aligning the allottee’s interests with the long-term performance of the underlying equity shares.
Historical Stock Returns for Halder Venture
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.35% | +1.09% | -3.13% | -12.54% | -14.19% | -14.19% |
How will the eventual conversion of these warrants by P.K. Bio Link Private Limited impact Halder Venture's existing promoter shareholding and control structure?
What specific strategic initiatives or capital expenditures does Halder Venture plan to fund with the proceeds from this warrant issuance?
Given the high premium of ₹305 per warrant, what is the implied conversion price, and how does it compare to the current market price of Halder Venture's equity shares?


































